Dexefaroxan

Drug Profile

Dexefaroxan

Alternative Names: L0046

Latest Information Update: 24 Apr 2007

Price : $50

At a glance

  • Originator Pierre Fabre
  • Class Antiparkinsonians; Benzopyrans; Imidazoles; Neuroprotectants; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease; Cognition disorders

Most Recent Events

  • 22 Aug 2003 Phase-I clinical trials in Alzheimer's disease in France (unspecified route)
  • 06 May 2003 A preclinical study has been added to the Alzheimer's disease pharmacodynamics section
  • 23 Apr 2001 Preclinical development for Cognition disorders in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top